For patients with primary RCC who are ineligible for surgical resection, SABR serves as a viable alternative. Data from the JAVELIN Renal 101, KEYNOTE-426, CheckMate 9ER, CLEAR, and IMmotion151 trials were reviewed. Dr. Kirsh discusses his distinguished career and the evolution of urology practice in the United States. RMC has a 3-year survival rate of less than 5% and responds poorly to other treatments for renal malignancies. Dr. Wei helped uncover genetic, transcriptional, and immune differences in TFE3-rearranged RCC versus papillary, ccRCC. FASTRACK II was the first trial of its kind to examine nonsurgical definitive therapy in patients with primary RCC. Drs. Beckermann and Hutson compare the QOL data for tivozanib and belzutifan in patients with relapsed or refractory aRCC. Drs. Hutson and Beckermann summarize the long-term TIVO-3 data for patients with relapsed or refractory advanced RCC. Dr. George shares his expert opinion on the 8-year CheckMate 214 survival and durable response data in advanced RCC. Dr. George provides an overview of the adjuvant pembro long-term data and the other adjuvant approaches being investigated. We spoke with clinicians about some of the disparities that exist, why they persist, and what might be done to correct them. NARUS served as a platform for surgeons to share insights into the advancements and future directions of robotic surgery. A new study on the prognostic value of perinephric fat, renal sinus fat, and renal vein invasion in patients with pT3a RCC. Researchers analyzed the data from patients who received anti–LAG-3 and anti–PD-1. While RLRN and TLRN procedures were found to have similar efficacy, TLRN also resulted in better surgical specimen integrity. Dr. Saby George continues with the survival implications and ramifications from the CheckMate 214 long-term data. Dr. Saby George provides details on CheckMate 67T for the utility of subcutaneous nivolumab for advanced or metastatic ccRCC. Dr. Powles gives his unique feedback on what to make of KEYNOTE-564 and how aRCC frontline options should be compared. The panel shared their excitement for the road ahead in kidney cancer. The panel addressed different dosing scenarios and shared tips on how to counsel patients on their treatment.